Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

Overview

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Retrospective
• Study Primary Completion Date: June 2015

Detailed Description

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. The presence of Livedoid vasculopathy must be confirmed by a histologic specimen. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia. The presence of a history of smoking and thrombophilia is compared to the general Swiss population.

Interventions

• Other: Thrombophilia screening
  • No intervention. Blood is drawn for analysis.

Arms, Groups and Cohorts

• Thrombophilia screening
  • Patients with livedoid vasculopathy. Investigated by thrombophilia screening

Clinical Trial Outcome Measures

Primary Measures

• Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.
  • Time Frame: 22 months
  • The primary endpoint is the comparison of a positive smoking history and other cardiovascular risk factors of patients with livedoid vasculopathy with the Swiss general population.

Secondary Measures

• Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans
  • Time Frame: 22 months
  • The secondary endpoint is the search for thrombophilia in patients with livedoid vasculopathy.

Participating in This Clinical Trial

Inclusion Criteria

• History of livedoid vasculopathy Exclusion Criteria:

• Diagnosis was not proved by biopsy specimen – A different reason than livedoid vasculopathy has been found for the symptoms of the patient – No informed consent by the patient

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • University of Zurich
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Juerg Hafner, Prof, MD, Principal Investigator, University Hospital Zurich, Dept. of Dermatology